Opus Genetics, Inc.
HealthcareNASDAQ:IRD · NASDAQ Global Market
+$0.13 today
Vol 0.69M · Avg 0.86M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-323.1%
avg -164.4%
ROIC
-90.9%
avg -47.4%
ROA
-98.7%
avg -134.2%
Analysis
ROIC is currently the strongest return metric at -90.9% versus its period average of -47.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
George Magrath | Chief Executive Officer & Director | $973,790.00 | — | 41 | $1.74M | 2.14% |
Ashwath Jayagopal | Chief Scientific & Development Officer | $682,360.00 | — | 43 | $509,233.00 | 0.63% |
Joseph K. Schachle | Chief Operating Officer | $635,920.00 | — | 61 | $296,084.00 | 0.36% |
Amy Zaremba Rabourn | Head of Financial Quality Assurance | $434,100.00 | — | 45 | $188,671.00 | 0.23% |
Bernhard Hoffmann | Senior Vice President of Corporate Development & Secretary | $434,100.00 | — | 70 | $185,446.00 | 0.23% |
Benjamin R. Yerxa | President & Director | — | — | 60 | $711,535.00 | 0.87% |
Jenny Kobin | Investor Relations Officer | — | — | — | — | — |
Sally Tucker | Chief Medical Officer & Senior Vice President of Clinical Development | — | — | — | — | — |
Chris Ernst | Chief Technology Officer | — | — | — | — | — |
Robert E. Gagnon | Chief Financial Officer & Principal Accounting Officer | — | — | 52 | $592,158.00 | 0.73% |
Bindu Manne | Head of Market Development & Commercialization | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$323,693.40
Sells
12
$16.38M
Net Sentiment
$16.05M
Net selling
Most Active
Foundation Fighting Blindness Retinal Degeneration Fund
2 transactions
1–10 of 14
Analysis
Insiders reported 2 buys worth $323,693.40 and 12 sells worth $16.38M over the last 12 months. That adds up to net selling of $16.05M. Foundation Fighting Blindness Retinal Degeneration Fund was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | +48.8% (7yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Forward estimates point to Revenue at +48.8% (7yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Alector, Inc.
NASDAQ:ALEC
$169.87M
TuHURA Biosciences, Inc.
NASDAQ:HURA
$147.74M
Acumen Pharmaceuticals, Inc.
NASDAQ:ABOS
$143.56M
Agenus Inc.
NASDAQ:AGEN
$137.42M
Seer, Inc.
NASDAQ:SEER
$94.57M
Cognition Therapeutics, Inc.
NASDAQ:CGTX
$89.03M
Inovio Pharmaceuticals, Inc.
NASDAQ:INO
$58.95M
Seres Therapeutics, Inc.
NASDAQ:MCRB
$55.20M
Instil Bio, Inc.
NASDAQ:TIL
$53.71M
VistaGen Therapeutics, Inc.
VTGN
$18.88M
Who manages IRD?
Opus Genetics, Inc. (IRD) lists 11 active executives. The top listed executive is Ashwath Jayagopal, Chief Scientific & Development Officer.
Are IRD insiders buying or selling?
Recent insider activity shows net selling of $11.46M.
Explore More
Continue the stock analysis
Jump to another research area for this company.